GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
Recruiting
Phase 4
Interventional Study
Myocardial Injury
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 372 (estimated)
- Sponsor
- The University of Hong Kong · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery. Recruited patients will be randomized in a 2:1 ratio to receive single subcutaneous dose of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RAs) 1 to 14 days prior to surgery or receive routine care.
Dulaglutide (Trulicity; Eli Lilly, USA…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 18 years
* Planned elective intermediate to high risk non-cardiac surgery
* Anticipated to remain hospitalized for at least one night after surgery
* Voluntarily agrees to participate by providing written informed consent
Exclusion Criteria:
* History of symptomatic hy…
Contacts